Brief: MBX Biosciences To Provide Topline Results From Its Phase 2 Trial Of Canvuparatide
19/09/2025 21:54
Sept 19 (Reuters) - MBX Biosciences Inc MBX.O: MBX BIOSCIENCES TO PROVIDE TOPLINE RESULTS FROM ITS PHASE 2 TRIAL OF POTENTIAL ONCE-WEEKLY CANVUPARATIDE FOR HYPOPARATHYROIDISM (HP) ON MONDAY, SEPTEMBER 22 Source text: ID:nGNX9bfNBN Further company coverage: MBX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MBX Biosciences
See all newsU.S. RESEARCH ROUNDUP-Health Catalyst, Nektar Therapeutics, TIC Solutions
MBX Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: MBX Biosciences Announces Executive Leadership Transition To Support The Company’S Next Phase Of Growth
MBX Biosciences falls after executive shakeup
U.S. STOCKS ON THE MOVE-SpaceX, Tesla, Woodside Energy Group